CorVista System with PH Add-On vs EchoGo® Heart Failure
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 70/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A provides a non-invasive, point-of-care AI diagnostic for coronary artery disease and pulmonary hypertension by analyzing cardiac and hemodynamic signals. In contrast, Tool B focuses on detecting Heart Failure with preserved Ejection Fraction (HFpEF) through the analysis of routine echocardiograms. While both are FDA-cleared AI platforms in cardiology, they utilize different data inputs and target distinct cardiovascular conditions, making them complementary for different diagnostic pathways.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
The CorVista System with PH Add-On is an FDA-cleared platform for the rapid assessment of coronary artery disease (CAD) and pulmonary hypertension (PH) using machine-learned algorithms. EchoGo Heart Failure is an AI platform that analyzes routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF).
The CorVista System is a non-invasive, point-of-care tool that analyzes cardiac and hemodynamic signals, requiring no radiation, contrast agents, injections, fasting, or exercise. In contrast, EchoGo Heart Failure analyzes existing routine echocardiogram video clips to provide insights into HFpEF.
The CorVista System collects data at the point-of-care, processes it in the cloud, and delivers results via a secure web portal. EchoGo Heart Failure is designed for seamless integration with existing workflows and IT stacks, utilizing a DICOM workflow for report delivery directly to PACS.
The CorVista System provides rapid results within minutes of the test being performed. EchoGo Heart Failure delivers insights to support clinical decisions within 20 minutes of analyzing routine echo video clips.
For the CorVista System, pricing information requires direct contact with the company. EchoGo Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers.
The CorVista System with PH Add-On has demonstrated algorithm performance in identifying patients with elevated mPAP with a sensitivity of 82% and specificity of 92% with a negative predictive value (NPV) of >99%. EchoGo Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF detection, and it was trained on over 10 years of outcome data.